The HERA Trial: Cardiac Events at 8 years median follow-up

TITLE OF PUBLICATION

Trastuzumab-associated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant Trial (HERA BIG 1-01)

AUTHORS

Evandro de Azambuja, Marion J. Procter, Dirk J. van Veldhuisen, Dominique Agbor-Tarh, Otto Metzger-Filho, Jutta Steinseifer, Michael Untch, Ian E. Smith, Luca Gianni, Jose Baselga, Christian Jackisch, David A. Cameron, Richard Bell, Brian Leyland-Jones, Mitch Dowsett, Richard D. Gelber, Martine J. Piccart-Gebhart, Thomas M. Suter

PUBLICATION REFERENCE

Journal of Clinical Oncology | Volume 32 | Issue 20 | Pages 2159-2165 | 10 July 2014

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more